Seems like an unusually high # of shares to be outstanding in a small cap biotech IPO, i.e., 41 million+.
Yeah, a fact of life after starting out with the big slug of private money and some stars. This is a slow ramp, heavy dilution plan. The hope is that leverage can be retained, and that the slow ramp will turn into a "sky".
Rick...Thoughts on adding shares of ARIA at $1 1/2 ? Looks like you get 8 for 1 TLRK.
Since the regulatory hurdles are enourmous, so I'm going to wait and watch. The MC:book is now so damn low -- it's really tempting. Still concerned about the separate toxicity testing for the dimerizer, however. I really want to see the technnology work, but I'm not certain that any pharmas do.
I'm not implying that I'm interested in Tularik as an investment, relatively speaking. I am, however, interested in seeing them under the "public company" magnifying glass, where I can more readilly evaluate their competitive status. |
